These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 26873529

  • 21. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
    Vanherpe P, Fieuws S, D'Hondt A, Bleyenheuft C, Demaerel P, De Bleecker J, Van den Bergh P, Baets J, Remiche G, Verhoeven K, Delstanche S, Toussaint M, Buyse B, Van Damme P, Depuydt CE, Claeys KG.
    Orphanet J Rare Dis; 2020 Apr 05; 15(1):83. PubMed ID: 32248831
    [Abstract] [Full Text] [Related]

  • 22. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
    Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A.
    J Neurol; 2017 Apr 05; 264(4):621-630. PubMed ID: 27372449
    [Abstract] [Full Text] [Related]

  • 23. White matter lesions in treated late onset Pompe disease are not different to matched controls.
    Schneider I, Hensel O, Zierz S.
    Mol Genet Metab; 2019 Jun 05; 127(2):128-131. PubMed ID: 31153821
    [Abstract] [Full Text] [Related]

  • 24. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
    Semplicini C, De Antonio M, Taouagh N, Béhin A, Bouhour F, Echaniz-Laguna A, Magot A, Nadaj-Pakleza A, Orlikowski D, Sacconi S, Salort-Campana E, Solé G, Tard C, Zagnoli F, Hogrel JY, Hamroun D, Laforêt P, French Pompe Study Group.
    J Inherit Metab Dis; 2020 Nov 05; 43(6):1219-1231. PubMed ID: 32515844
    [Abstract] [Full Text] [Related]

  • 25. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
    Harlaar L, Hogrel JY, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, Canal A, Brusse E, van Doorn PA, van der Ploeg AT, Laforêt P, van der Beek NAME.
    Neurology; 2019 Nov 05; 93(19):e1756-e1767. PubMed ID: 31619483
    [Abstract] [Full Text] [Related]

  • 26. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P.
    Mol Genet Metab; 2012 Dec 05; 107(4):669-73. PubMed ID: 23146291
    [Abstract] [Full Text] [Related]

  • 27. Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.
    Berger KI, Chien YH, Dubrovsky A, Kishnani PS, Llerena JC, Neilan E, Roberts M, Sheng B, Batista JL, Periquet M, Wilson KM, van der Ploeg AT.
    J Neurol; 2024 Aug 05; 271(8):5433-5446. PubMed ID: 38896264
    [Abstract] [Full Text] [Related]

  • 28. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
    van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, Kishnani PS, Laforêt P, Morgan C, Nations S, Pestronk A, Plotkin H, Rosenbloom BE, Sims KB, Tsao E.
    Mol Genet Metab; 2012 Nov 05; 107(3):456-61. PubMed ID: 23031366
    [Abstract] [Full Text] [Related]

  • 29. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
    Moriggi M, Capitanio D, Torretta E, Barbacini P, Bragato C, Sartori P, Moggio M, Maggi L, Mora M, Gelfi C.
    Int J Mol Sci; 2021 Mar 11; 22(6):. PubMed ID: 33799647
    [Abstract] [Full Text] [Related]

  • 30. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
    Hundsberger T, Schoser B, Leupold D, Rösler KM, Putora PM.
    J Neurol; 2019 Aug 11; 266(8):2010-2017. PubMed ID: 31104135
    [Abstract] [Full Text] [Related]

  • 31. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
    Hundsberger T, Rösler KM, Findling O.
    J Neurol; 2014 Sep 11; 261(9):1684-90. PubMed ID: 24923245
    [Abstract] [Full Text] [Related]

  • 32. Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months.
    Schneider I, Hanisch F, Müller T, Schmidt B, Zierz S.
    Wien Med Wochenschr; 2013 Jan 11; 163(1-2):40-4. PubMed ID: 23160972
    [Abstract] [Full Text] [Related]

  • 33. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
    Toscano A, Schoser B.
    J Neurol; 2013 Apr 11; 260(4):951-9. PubMed ID: 22926164
    [Abstract] [Full Text] [Related]

  • 34. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
    Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, Laforêt P, Mengel KE, Peña LDM, Sacconi S, Straub V, Trivedi J, Van Damme P, van der Ploeg AT, Vissing J, Young P, Haack KA, Foster M, Gilbert JM, Miossec P, Vitse O, Zhou T, Schoser B, NEO-EXT investigators.
    Neurology; 2022 Aug 01; 99(5):e536-e548. PubMed ID: 35618441
    [Abstract] [Full Text] [Related]

  • 35. [The long-term follow-up of enzyme replacement treatment in late onset Pompe disease].
    Molnár MJ, Borsos B, Várdi KV, Grosz Z, Sebők Á, Dézsi L, Almássy Z, Kerényi L, Jobbágy Z, Jávor L, Bidló J.
    Ideggyogy Sz; 2020 May 30; 73(05-06):151-159. PubMed ID: 32579304
    [Abstract] [Full Text] [Related]

  • 36. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS, Beckemeyer AA.
    Pediatr Endocrinol Rev; 2014 Sep 30; 12 Suppl 1():114-24. PubMed ID: 25345093
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
    Scheidegger O, Leupold D, Sauter R, Findling O, Rösler KM, Hundsberger T.
    J Neurol; 2018 Dec 30; 265(12):2783-2788. PubMed ID: 30232608
    [Abstract] [Full Text] [Related]

  • 39. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH, Hwu WL, Lee NC.
    Pediatr Neonatol; 2013 Aug 30; 54(4):219-27. PubMed ID: 23632029
    [Abstract] [Full Text] [Related]

  • 40. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
    Filosto M, Cotti Piccinelli S, Ravaglia S, Servidei S, Moggio M, Musumeci O, Donati MA, Pegoraro E, Di Muzio A, Maggi L, Tonin P, Marrosu G, Sancricca C, Lerario A, Sacchini M, Semplicini C, Bozzoni V, Telese R, Bonanno S, Piras R, Maioli MA, Ricci G, Vercelli L, Galvagni A, Gallo Cassarino S, Caria F, Mongini T, Siciliano G, Padovani A, Toscano A.
    Adv Ther; 2019 May 30; 36(5):1177-1189. PubMed ID: 30879255
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.